HYPR · Hyperfine, Inc.
$0.93
-0.05 (-5.19%)
At close · Jul 17
Market Cap
$92.39M
Shares
99.27M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Maria Sainz | CEO | $896,817 |
| Thomas Teisseyre | COO | $799,634 |
| Brett Hale | CFO | $799,634 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Maria Sainz | CEO | $2,269,229 |
| Brett Hale | CFO | $1,053,316 |
| Thomas Teisseyre | COO | $1,053,316 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Brett Hale | CFO | $1,810,267 |
| Thomas Teisseyre | COO | $1,073,239 |
| Maria Sainz | CEO | $847,000 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Maria Sainz | CEO | $3,517,249 |
| Dave Scott | CEO | $3,045,496 |
| Khan Siddiqui | Chief Medical Officer and Chief Strategy Officer | $1,534,072 |
| Scott White | Chief Commercial Officer | $1,495,760 |
| Scott Huennekens | CEO | $1,394,479 |
| Alok Gupta | CFO | $734,371 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Dave Scott | CEO | $8,900,316 |
| Neela Paykel | General Counsel | $587,516 |
| Khan Siddiqui | Chief Medical Officer and Chief Strategy Officer | $583,445 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Khan Siddiqui | Chief Medical Officer and Chief Strategy Officer | $899,449 |
| Neela Paykel | General Counsel | — |
| Dave Scott | CEO | — |